Market Cap
$6.2B
LGND
LIGAND PHARMACEUTICALS INC
$304.95 ▲ +0.73%
Prev close $302.74Market cap$6.2B
ConsensusStrong Buy
12-mo target$344.25 (+12.9%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)30 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on LGND right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$5.6B
Inst. Activity
30 buys / 16 sells
Insider Activity
$0.00 buy / $20.7M sell
Insider Net $
-$20.7M
SEC Reports
9
Press Releases
1
Congressional
2 trades
Price chart 30d +6.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 other
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CA
Sep 22, 2026 Insider
Sep 14, 2026 SEC Zimmermann Martine surrendered for taxes 115 shares
Director @ $298.50 ($34.3K)
Two insiders at Ligand Pharmaceuticals sold a combined $427K in open-market transactions over a one-week window. The sal
CLUSTER — Impact 3/10
Sep 10, 2026 Insider
Zimmermann Martine sold 1,200 shares
Director @ $285.00 ($342.0K)
Sep 3, 2026 Insider
Aug 14, 2026 SEC Reardon Andrew sold 400 shares
CLO & Secretary @ $288.98 ($115.6K)
CFO Octavio Espinoza and Director Jason Haas executed a cluster of derivative exercises and open-market sales on August
CLUSTER — Impact 4/10
Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY royalty revenue gro
8-K — Impact 7/10
Jun 30, 2026 Inst.
FMR LLC — ADD
762,827 shares ($241.1M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | Barclays | INITIATE | Overweight | 54% |
| Sep 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 23, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Aug 14, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Aug 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 3, 2026 | Oppenheimer | REITERATE | Outperform | 52% |
| Jul 15, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 9, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| Jul 8, 2026 | Stifel | MAINTAIN | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Price targets
Where 12 covering analysts think LGND trades over the next 12 months.
$344.25 +12.9% upside Buy
Current$304.95 Low$247.00 Median$345.00 High$397.00 12 analysts
$247.00$397.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 0 bearish, 1 mixed, 6 neutral · avg impact 4.2/10.Plus 1 press releases.
NEUTRALCLUSTER3/10
Two insiders at Ligand Pharmaceuticals sold a combined $427K in open-market transactions over a one-
Sep 14, 2026
NEUTRALCLUSTER4/10
CFO Octavio Espinoza and Director Jason Haas executed a cluster of derivative exercises and open-mar
Aug 14, 2026
BULLISH8-K7/10
Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY
Aug 6, 2026
MIXED8-K6/10
Ligand Pharmaceuticals issued $700M of 0.00% Convertible Senior Notes due 2031, with an initial conv
Jun 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
other
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Sep 11, 2026
ftd
FTD: LGND — 2,018 shares ($0.6M) failed to deliver
Settlement: 20260911, Price: $289.25, FTD Value: $583,706.5, LIGAND PHARMACEUTICALS INC COM
Sep 3, 2026
ftd
FTD: LGND — 5,586 shares ($1.6M) failed to deliver
Settlement: 20260903, Price: $286.92, FTD Value: $1,602,735.12, LIGAND PHARMACEUTICALS INC COM
Aug 26, 2026
other
Ligand to Participate in September Investor Conferences
Ligand to Participate in September Investor Conferences
Aug 14, 2026
ftd
FTD: LGND — 6,144 shares ($1.8M) failed to deliver
Settlement: 20260814, Price: $288.82, FTD Value: $1,774,510.08, LIGAND PHARMACEUTICALS INC COM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.31 | $1.93–$2.49 | -25.3% | +0.2% | 1↑ 5↓ | $0.1B | 10 |
| Next Q | $2.99 | $2.79–$3.20 | 48.1% | -0.5% | 4↑ 2↓ | $0.1B | 10 |
| Current FY | $9.31 | $9.09–$9.50 | 14.5% | -0.1% | 4↑ 2↓ | $0.3B | 10 |
| Next FY | $11.95 | $10.51–$13.46 | 28.4% | +0.1% | 3↑ 1↓ | $0.4B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.309 | — |
| 7d ago | $2.303 | +0.006 |
| 30d ago | $2.303 | +0.006 |
| 60d ago | $2.556 | -0.247 |
| 90d ago | $2.509 | -0.200 |
Institutional ownership
Which big funds own LGND (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $5.6B total value (17,317,723 shares) as of 2026-Q2. Top holders: BlackRock,, Invesco, VANGUARD. Net buying activity: 30 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,100,996 | $980.2M | 17.5% | — |
| Invesco Ltd. | 1,201,644 | $379.8M | 6.8% | ADD +59.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,138,316 | $359.8M | 6.4% | — |
| Jupiter Topco LLC | 1,040,578 | $328.9M | 5.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 870,950 | $275.3M | 4.9% | — |
| STATE STREET CORP | 826,539 | $261.3M | 4.7% | — |
| FMR LLC | 762,827 | $241.1M | 4.3% | ADD +28.0% |
| FRANKLIN RESOURCES INC | 752,044 | $237.7M | 4.3% | — |
| CONGRESS ASSET MANAGEMENT CO | 659,911 | $208.6M | 3.7% | ADD +30.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 589,020 | $186.2M | 3.3% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 596,127 | 762,827 | +28.0% | $241.1M |
| CONGRESS ASSET MANAGEMENT CO | ADD | 504,637 | 659,911 | +30.8% | $208.6M |
| Neuberger Berman Group LLC | DOUBLED | 1,462 | 248,355 | +16887.3% | $78.5M |
| Aberdeen Group plc | ADD | 90,044 | 172,480 | +91.6% | $54.5M |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 3,356 | 127,071 | +3686.4% | $40.2M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 34,915 | 94,072 | +169.4% | $29.7M |
| OSAIC HOLDINGS, INC. | ADD | 58,150 | 90,236 | +55.2% | $28.5M |
| Fiera Capital Corp | TRIM | 135,312 | 77,348 | -42.8% | $24.4M |
| CITIGROUP INC | DOUBLED | 21,594 | 66,639 | +208.6% | $21.1M |
| NOMURA HOLDINGS INC | TRIM | 114,355 | 61,938 | -45.8% | $19.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$20.7M — $0.00 bought, $20.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Zimmermann Martine | Director | TAX W/H | 115 | $298.50 | $34.3K |
| Sep 10, 2026 | Zimmermann Martine | Director | SELL | 1,200 | $285.00 | $342.0K |
| Sep 3, 2026 | Reardon Andrew | CLO & Secretary | SELL | 400 | $288.98 | $115.6K |
| Sep 3, 2026 | Reardon Andrew | CLO & Secretary | SELL | 385 | $287.53 | $110.7K |
| Sep 3, 2026 | Reardon Andrew | CLO & Secretary | SELL | 2,115 | $286.36 | $605.6K |
| Sep 3, 2026 | Reardon Andrew | CLO & Secretary | SELL | 1,800 | $285.17 | $513.3K |
| Sep 3, 2026 | Reardon Andrew | CLO & Secretary | SELL | 300 | $283.99 | $85.2K |
| Aug 12, 2026 | Haas Jason | Director | EXERCISE | 6,138 | $51.56 | $316.5K |
| Aug 12, 2026 | Espinoza Octavio | Chief Financial Officer | EXERCISE | 2,869 | $55.75 | $159.9K |
| Aug 12, 2026 | Espinoza Octavio | Chief Financial Officer | EXERCISE | 3,348 | $68.74 | $230.1K |
Congressional trades
LGND trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Ligand Pharmaceuticals Inc | Feb 16, 2026(33d) |
| Jan 5, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Ligand Pharmaceuticals Inc | Feb 16, 2026(43d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LGND.
Shares short
2,632,434
Settlement Sep 15, 2026
Change vs prior
+6.1%
Semi-monthly cycle
Days to cover
13.5
At avg daily volume
Of shares outstanding
≈13.2%
Estimate — not % of float
All LGND filing & press-release reports (10)
- CLUSTER reportSep 14, 2026
- CLUSTER reportAug 14, 2026
- 8-K reportAug 6, 2026
- 8-K reportJun 26, 2026
- CLUSTER reportJun 18, 2026
- CLUSTER reportJun 16, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportMay 15, 2026
- PRESS-RELEASE reportApr 14, 2026
- 8-K reportFeb 26, 2026